Lupin is offering zileuton extended-release tablets, in a dosage strength of 600 mg.
The product is the generic equivalent of Chiesi USA’s Zyflo CR extended-release tablets, 600 mg.
It is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
Zileuton extended-release tablets had a market value of approximately $40 million, according to IQVIA June 2020 data.
Lupin's product will be manufactured at Lupin’s Nagpur, India facility.